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A B S T R A C T
Purpose: The goal of the study was to assess the outcome of antiepileptic drug (AED) withdrawal in
children and adolescents with cryptogenic focal epilepsies (CFE).
Methods: Medical records of consecutive patients with CFE from two referral hospitals were
retrospectively evaluated over a nine-year period. Inclusion criteria were: (1) diagnosis of CFE according
to the ILAE criteria, (2) less than 16 years of age at onset of epilepsy, (3) established clinical remission of at
least two years before AED withdrawal, and (4) follow-up period of at least two years after withdrawal (or
until seizure relapse in patients who relapsed). Time to seizure relapse and predictive factors were
analyzed by survival methods.
Results: The cohort consisted of 52 patients (16 females, 36 males). Relapse rate was 37.85%. Most
relapses occurred during the ﬁrst 12 months after withdrawal. Univariate analyses indicated the
following factors as signiﬁcantly correlated with seizure recurrences: (1) female sex; (2) age at
withdrawal of AED 14 years or higher; (3) abnormal EEG before withdrawal; and (4) abnormal EEG during
and after AED withdrawal. Multivariate Cox regression analyses revealed that female sex, age at
withdrawal of AED 14 years or higher; and abnormal EEG during and after withdrawal were signiﬁcant
independent predictive factors for seizure recurrences.
Conclusion: The relapse rate in our cohort was similar to the most commonly reported overall rates for
childhood-onset epilepsy. Distinguishing variables—female sex, age at withdrawal greater than 14 years,
and abnormal EEG – need to be considered when choosing and further following of eligible candidates for
AED withdrawal.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at SciVerse ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
The issue of antiepileptic drug (AED) withdrawal in patients
with clinical remission of seizures still draws the attention of
physicians involved in the management of patients with epilepsy.
This issue becomes more intriguing when it refers to children and
adolescents. Anticipating outcomes in the natural disease course in
these young populations is often an uneasy task.
The numerous AED withdrawal studies published in the last 40
years have relied mainly on heterogeneous study groups. It has
become clear that focusing attention on etiologically and electro-
clinically more homogeneous study groups might facilitate* Corresponding author at: Al Sabah Hospital, Pediatric Department, Pediatric
Neurology Unit, 31 470 Kuwait. Tel.: +96524827347.
E-mail address: milen_p@ptt.rs (M. Pavlovic´).
1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.04.008implementation of outcome predictive ﬁndings into the clinical
management of particular groups of patients.
The Commission on Classiﬁcation and Terminology of the
International League Against Epilepsy (ILAE) in 19891 designated
cryptogenic epilepsy as epilepsy for which an etiology is unknown,
but an underlying brain disease is suspected. In the year 2010, the
commission revised concepts, terminology, and approaches for
classifying seizures and forms of epilepsy.2 According to this
revision, the term ‘‘cryptogenic’’ was replaced with ‘‘unknown’’.
Because of the pragmatic utility to maintain the already rooted
terminology, however, we will continue to use the term
‘‘cryptogenic epilepsies’’. These epilepsies account for one-third
or more of all childhood epilepsies3 and more than half of
childhood non-idiopathic localization-related epilepsies.4 Current-
ly not fully understood, cryptogenic focal epilepsy (CFE) in children
and adolescents has a non-predictable course and prognosis.3,5
A considerable amount of published literature on AED
withdrawal reveals only a few studies speciﬁcally related to thevier Ltd. All rights reserved.
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idea of the authors was to highlight this aspect of prognosis by
analyzing withdrawal outcome in a selected group of pediatric CFE.
2. Patients and methods
2.1. Time and setting
This study was part of a larger observational study of
probability of recurrence of seizures upon AED withdrawal in a
younger population, which encompassed patients with different
etiologies and types of epilepsy. The study was conducted over a
nine-year period, from January 2001 through December 2009.
The subjects, children and adolescents with epilepsy undergo-
ing AED withdrawal process, or having been weaned from AED,
were identiﬁed among consecutive follow-up outpatients from
two regional referral university hospitals: Institute for Child and
Adolescent Health Care in Novi Sad and Clinic of Neurology and
Psychiatry for Children and Youth in Belgrade, Serbia (85 km from
each other). These tertiary-level hospitals collect patients referred
by pediatricians from primary and secondary health care levels.
The subjects were seen, diagnosed, and treated by child
neurologists and/or neuropaediatricians/epileptologists in the
usual outpatient follow-up intervals of three–six months. The
records of these patients were retrospectively screened for the
occurrence of a relapse after AED withdrawal in the mentioned
period. The ﬁnal evaluation of the seizure status of suitable
patients was conducted on December 31, 2009.
2.2. Deﬁnitions
The diagnosis of epilepsy was ascertained on clinical and
neurophysiological grounds. We deﬁned epilepsy as the occur-
rence of two or more unprovoked seizures or a single unprovoked
seizure with accompanying epileptic discharges on EEG. For
etiological determination of epilepsy, we used ILAE criteria.1
Accordingly, CFE was deﬁned as localization-related epilepsy
where no deﬁnitive etiological pathology could be established.
Patients with mental retardation (either clinically or based on
applied neuropsychological tests, i.e. IQ < 70), global developmen-
tal delay, and neurological deﬁcits were referred to symptomatic
focal epilepsies. Patients whose clinical and EEG features were
consistent with benign epilepsy with rolandic spikes, benign
epilepsy with occipital spikes, and benign infantile focal epilepsies,
were referred to the group of idiopathic focal epilepsies. Seizures
were classiﬁed as focal (simple/complex) and/or generalized
(secondarily generalized).
2.3. Inclusion criteria
The main inclusion criteria were: (1) diagnosis of CFE according
to ILAE; (2) age at onset of epilepsy of less than 16 years; (3)
established clinical remission of at least two years before AED
withdrawal; (4) follow-up period of at least two years after
withdrawal or until seizure relapse in patients who relapsed.
2.4. Withdrawal process
The withdrawal of AED was performed gradually in variable
periods, with durations ranging from six to 12 months. When
patients were taking two or more AEDs, withdrawal started by
reducing one of the AEDs ﬁrst. Withdrawal of the next AED began
when the previous drug had been completely discontinued. The
AED withdrawal was cancelled if the seizures recurred during the
withdrawal course. Timing of the decision to attempt withdrawal
was completely up to the physician.2.5. Diagnostic evaluation and follow-up
EEG in both settings was recorded according to the interna-
tional 10–20 electrode placement system (21 channels), using
Oxford Medilec EEG machines. Video EEG has been available for
the last six years, and since then, it has been used as routine
monitoring. Combined awake–sleep EEG of 30–45 min duration
was the established procedure for the AED withdrawal monitoring.
EEG readings were conducted at least once during the withdrawal
and every three to six months in the post-withdrawal follow-up
period.
EEG interpretations through the course of the disease were
evaluated by the authors consensus. The interictal EEG abnormali-
ties included focal and/or generalized epileptiform changes
(spikes, sharp waves, and spike/wave complexes). In case of only
generalized epileptiform discharges, the diagnosis of focal epilep-
sies was based, along with asymmetrical appearance of epilepti-
form discharges, on their ictal clinical focal semiology (if witnessed
by physician, derived from patient history or by video record).
For the purpose of the study, we reviewed in particular EEG
recordings before, during and after AED withdrawal. According to
common practice, normalization of EEG was in favor of starting
withdrawal process. The presence of pre-withdrawal focal (but not
generalized) abnormalities, along with good seizure control, was
not considered an obstacle to enter AED withdrawal process.
Possible inﬂuences of EEG location or lateralization of epileptic
focal discharges during the clinical course were not analyzed, due
to known difﬁculties in precise topographic diagnosis of CFE,
including the ﬂuctuating tendency of interictal EEG abnormalities
to diffusion and side shifting.9
Patients without neuro-imaging ﬁndings: computerized to-
mography (CT) and/or magnetic resonance imaging (MRI), were
not considered eligible for the study.
2.6. Assessment of recurrence risk
The main outcome endpoint in our study was seizure relapse.
To identify outcome predictors, the following variables, derived
from the case records, were analyzed: sex; age at seizure onset;
types of seizures (focal and/or generalized); history of status
epilepticus; EEG ﬁndings before, during, and after AED withdraw-
al; AED treatment (monotherapy versus polytherapy and drugs
used in monotherapy); duration of AED therapy; seizure freedom
while on AED; age at the start of AED withdrawal; history of febrile
seizures; family history of epilepsy; and perinatal history. These
variables were entered into the computerized patient database. As
the treatment was installed at the very onset of the disease (no
later than after the second or third attack), the period before the
initiation of treatment was not considered a potential relapse
predictor.
2.7. Statistical analysis
As the main outcome measure was seizure relapse, time to
seizure relapse was analyzed by the Kaplan Meier method to
illustrate the likelihood of seizure recurrences. The differences
between the frequencies of categorical variables were assessed by
x2 test. The risk for recurrence during the follow-up was
investigated by the Cox proportional hazard model (uni/multivar-
iate analyses)10 to allow for variable length of follow-up. Outcome
predictive factors were modeled according to the hazard ratio (HR)
followed by the 95% conﬁdence interval (CI). Variables for
multivariate analysis were selected from the results of univariate
analyses. Statistical signiﬁcance was accepted at p < 0.05. The SPSS
version 16.0 software package (SPSS Inc., Chicago, IL) was used for
statistical analysis.
Table 1
General features of study cohort.
Sex (f/m) 16 (30.8%)/36 (69.2%)
Age at end of study (median, range) 18.5 (11–26) years
Age at seizure onset (median, range) 7.5 (4.5–16) years
Type of seizures (focal, generalized) 14 (26.9%)/38 (63.1%)
Treatment duration (median, range) 5 (2–14) years
Seizure-free period before AED
withdrawal (median, range)
4 (2–12) years
Time to seizure control (median, range) 1 (1–6) years
Age at AED withdrawal (median range) 14 (6–20) years
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3.1. Study cohort/general features
The study cohort of CFE patients was derived from the larger
cohort, initially consisting of 148 patients with focal epilepsies
who underwent AED discontinuation (38 females, 110 males). Due
to being non-responders to follow-up or attending other clinics (16
patients), or due to missing neuroimaging data necessary for the
etiological classiﬁcation (7 patients), 23 patients were dropped
from the study. Upon exclusion of those patients, 125 patients
entered the study (Fig. 1). Of the 125 patients in the study, 84
patients (68.3%) were classiﬁed as having non-idiopathic (crypto-
genic and symptomatic) focal epilepsy. Of those 84 patients, 52
(61.90%) patients were assigned as patients with CFE (34 patients
came from the area covered by the Belgrade center and 18 patients
from the area covered by Novi Sad center).
In CFE cohort, most of the patients were males 36 (69.2%). The
median age at seizure onset was 7.5 years. Fourteen children
presented with only partial seizures, and 38 with generalized
tonic–clonic seizures. Of the 38 patients with generalized seizures,
14 presented only with immediate generalized seizures, and the
others had both focal and generalized (tonic or tonic–clonic)
seizures in their histories. Regarding the types of focal seizures, 31
patients presented with complex focal seizures, and seven patients
presented with simple focal seizures. There was a history of
convulsive status epilepticus in three patients.
In most of the patients – 32 (61.3%)-seizure control was
established during the ﬁrst year since the beginning of treatment.
In 12 patients, it occurred in the 1–3 year period, in seven patients
in the 3–5 year period, and in one patient, in 6 years.
The median age at AED withdrawal was 14 years: eight patients
at 6–10 years of age, 26 patients at 10–15 years of age, and 18
patients at 16–20 years of age.
The median duration of seizure-free periods before withdrawal
was 4 years. In most of the patients, 48 of the 52 (92.3%), thatFig. 1. Flowchart showing recruitment of patients for the study.period lasted more than 2.5 years: in 28 patients, 2.5–4 years; in 12
patients, 4.5–6 years; in seven patients, 7–8 years, and in one
patient, 12 years.
The median follow-up since the beginning of AED withdrawal in
patients who did not relapse was four years. Twenty-ﬁve (75.8%)
patients were followed for more than two years: 16 (48.5%) were
followed for 3–5 years, six (17.3%) for 6–8 years, one for 9 years,
one for 10 years, and one for 13 years.
Regarding somatic co-morbidities, there were two patients
with bronchial asthma.
The characteristics of the study group are summarized in Table
1.
3.2. Rate and time of seizure relapse
Until the end of observational period, 19 out of 52 (35.85%)
patients with CFE relapsed; of those 19 patients, 13 (72.2%) had
focal seizures and six had secondarily generalized seizures.
Most relapses (73.7%) occurred during the ﬁrst 12 months since
the beginning of the AED withdrawal, particularly during the ﬁrst
seven months (57.9%) since the beginning of AED withdrawal. In
three of the 19 patients who relapsed, seizures recurred during the
withdrawal period. After the ﬁrst 12 months, as shown at Fig. 2, the
probability of having relapses was markedly decreased. The
occurrences of relapses, after 12 months since the withdrawal,
were at the following times: 18 months (1), 24 months (1), 36
months (1), and 60 months (1).
3.3. Differences relating to the occurrence of relapse
The differences relating to the occurrence of relapses are shown
in Table 2.
Females had more relapses than males; this association was
statistically signiﬁcant.
Regarding the pre-withdrawal EEG recordings, patients with
relapses more frequently had abnormal EEGs than those without
relapses, and the difference showed statistical signiﬁcance.
In six out of 41 patients with normal pre-withdrawal EEGs,
through the period during (3 patients) and after (3 patients)
withdrawal, focal epileptiform abnormalities of variable severity
reappeared. Regarding those with pre-withdrawal abnormalities,
in two out of 11 patients, EEGs normalized in the follow-up, and
remained abnormal in nine patients. Therefore, upon completion
of AED withdrawal, there were 12, and, through the further follow-
up to the end of the study there were an additional three, for a total
of 15 patients with abnormal EEGs.
With respect to above-mentioned EEG changes during and after
withdrawal, patients with relapses more frequently had abnormal
EEG in these periods. The difference was statistically signiﬁcant.
Patients whose median age at AED withdrawal was 14 years or
older had a signiﬁcantly higher rate of relapse. Patients whose
median age at seizure onset was 7.5 years or older had a higher rate
  Probability of remaining seizure-free 
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Fig. 2. Cumulative probability of seizure relapses following AED withdrawal, shown
as the Kaplan–Meier survival curve. The interval between AED withdrawal and
seizure relapse on the x-axis is indicated in months. Time 0 indicates the beginning
of AED withdrawal.
M. Pavlovic´ et al. / Seizure 21 (2012) 431–436434of relapse. The difference tended toward but did not reach
determined statistical signiﬁcance.
No other variable showed statistical signiﬁcance.
Although not considered a variable of predictive potential, we
compared the groups with and without MRI. In the subgroup ofTable 2
Possible predictors and corresponding relapse rate.
Variable Total (N) 
Sex Female 16 
Male 36 
Age at epilepsy onset (years) <7.5 25 
>7.5 27 
Type of seizure Focal 14 
Generalized 38 
EEG at withdrawal Normal 41 
Abnormal 11 
EEG during/after withdrawal Normal 37 
Abnormal 15 
AED treatmentc Monotherapy 42 
Polytherapy 10 




Duration of AED therapy (years) <5 31 
>5 21 
Seizure-free on AED therapy (years) <4 34 
>4 18 
Age at withdrawal (years) <14 25 
>14 27 
Perinatal history Normal 42 
Abnormal 10 
Febrile seizures Yes 10 
No 42 
Family history of epilepsya Yes 12 
No 40 
a Family history of epilepsy was noted in 12 (23.07%) patients: ﬁrst-grade relatives 
b NS: non-signiﬁcant.
c Regarding the AED treatment before withdrawal, monotherapy was carried out in
patients, both CBZ and VPA (as switch on monotherapy) in seven patients, and one patien
and VPA in six patients, and four patients were treated by VPA and lamotrigine (LMT). D
four patients were treated by VPA and lamotrigine (LMT).patients who had MRIs (42), the relapse rate was in 15 of 78
(35.71%), while in the group who had CT only (10), the relapses
occurred in four (40%) patients (NS).
Cox regression analysis was performed to estimate the
magnitude and signiﬁcance of risks that variables of potentially
predictive value have for seizure recurrences during follow-up
(Table 3). According to univariate analysis, signiﬁcant predictors
were: female sex; abnormal EEG before withdrawal; abnormal EEG
during and after AED withdrawal; and age at AED withdrawal
above 14 years. As independent risk factors for seizure relapse
according to the multivariate analysis, three remained: abnormal




The proportion of patients with CFE within the total cohort of FE
who underwent AED withdrawal, as well as within the non-
idiopathic group of FE, corresponds to usual representation of CFE
in populations of patients with epilepsies.4 Deﬁnitions applied to
cryptogenic epilepsies have varied across studies, thus limiting
comparison. We did not include patients with cognitive delay asTotal (%) Relapse (N) Relapse (%) p
30.76 8 41.10
69.24 11 58.90 0.05
48.07 7 36.84
51.93 12 83.16 0.082
26.93 5 16.32 NSb
73.07 14 73.68
78.84 12 63.16 0.001
21.16 7 36.84
63.6 8 42.10 0.001
36.4 11 57.89
80.76 15 78.95 NS
19.14 4 21.05




59.62 11 57.90 NS
40.38 8 42.10
65.39 12 63.15 NS
34.61 7 36.85
48.18 7 36.85 0.082
51.92 12 63.15
80.77 14 73.69 NS
19.23 5 26.31
19.24 4 21.06 NS
80.76 15 78.94
23.08 5 26.32 NS
76.92 14 73.68
in three patients, and second-degree relatives in nine.
 41 (78.9%) patients: carbamazepine (CBZ) in 24 patients, valproate (VPA) in nine
t was on phenobarbital. Ten patients were treated simultaneously by two AEDs: CBZ
uring the clinical course, six patients were treated simultaneously by CBZ and VPA;
Table 3
Signiﬁcant predictors of seizure relapse: uni/multivariate analysis.
Variable Univariate analysis Multivariate analysis
HR (95% CI)a p HR (95% CI)a p
Abnormal EEG during/after withdrawal 3.35 (1.75–6.42) 0.001 4.15 (1.90–9.04) 0.001
Female sex 2.91 (1.46–5.82) 0.002 2.11 (1.02–4.38) 0.043
Age at withdrawal >14 years 2.67 (1.31–5.46) 0.007 2.78 (1.27–6.04) 0.010
Abnormal EEG at withdrawal 1.49 (1.02–2.19) 0.039 – –
a HR: hazard ratio, CI: conﬁdence interval.
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possible confounders assuming potential symptomatic etiology.
The size of the CFE group may not look impressive, but, along
with our inclusion and diagnostic criteria, it does reﬂect the
withdrawal rate in these patients in the period studied.
4.2. Relapse rate
In our study, the overall relapse rate after discontinuation of
antiepileptic medication was 36.5% after two years of seizure
freedom and for the median of four-year follow-up. This rate is
consistent with the most commonly reported rate of relapses (30–
40%) upon discontinuation of AED for childhood-onset epilep-
sy.11,12 Yet, it is markedly higher than the one reported in the
comparable study of Ohta et al.8, who reported a rate of 8.9% for a
similar follow-up period. Verrotti et al.6, within a CFE cohort of
seizure-free children with a normal EEG before withdrawal, found
the rate of relapse to be 27%, which is closer to the results of our
study. Actually, if patients with abnormal pre-withdrawal EEG in
our study had been excluded, the relapse rate would have been
even closer (29.27%). As proposed by Berg et al.13, the relapse risk
after withdrawal can be considered in the wider context of a wave-
like pattern of seizure remission and relapse course in patients
with CFE.
Most recurrences occurred in the ﬁrst year after withdrawal,
which is consistent with many previous studies12,13 and seems to
be the most consistent ﬁgure of AED withdrawal studies,
regardless of the features of the study groups.
4.3. Predictive factors for relapse
From a clinical point of view, the essential question is: are there
predictive variables for seizure relapse in children with CFE who
are candidates for AED withdrawal? According to the results of our
study, three variables appeared to be signiﬁcantly associated with
withdrawal outcome.
a) The signiﬁcantly higher risk for relapse in girls after AED
withdrawal might be a reﬂection of the male predominance
over females in the study cohort of CFE. It also was noted in the
total cohort of FE patients from whom this CFE cohort was
derived. Hence, it might be a possible consequence of selection
bias. Supposed referral bias related to males more commonly
being referred to epilepsy clinics than females has not been
recognized. This ﬁnding also may reﬂect a lower rate of
withdrawal in female patients, due to either more severe focal
epilepsies or more reluctance to enter the withdrawal process.
However, some other studies with mixed epilepsy cohorts14,16
also found this association. In two studies, this trend was
noticed in females with idiopathic epilepsies.15,17
b) Age of AED withdrawal of 14 years or older as a signiﬁcant risk
factor for relapse is in accordance with the ﬁndings of the study
of Ohta et al.8 In that study, this age cut-off at 15 years was
correlated to the older age of onset of epilepsy as a signiﬁcant
predictor for seizure relapse. In our study, the age at onset was
found to be near signiﬁcant level, which, in a way, correlateswith the ﬁndings of the mentioned and some other studies.15
Some other studies with heterogeneous cohorts, did not conﬁrm
this association.18,19
c) Regarding the very controversial issue about whether or not the
EEG ﬁndings before withdrawal inﬂuence the outcome,
reported results vary widely.11,12,17 Our ﬁndings support the
view of predictive value of pre-withdrawal EEG in selecting
patients for AED withdrawal, according to univariate, but not
multivariate analysis. It is in accordance with some studies,19,20
but not with others.12,16
A signiﬁcant relationship was also found between abnormal
EEG during and after AED withdrawal and prognosis. This ﬁnding
supports rare studies that considered EEG during and/or after
withdrawal. Verrotti et al.7 pointed to the reappearance of EEG
abnormalities during AED withdrawal as a risk factor for relapse in
patients with CFE. Olmeza et al. and Todt et al.16,18 found post-
withdrawal EEG to be a risk factor for relapse in heterogeneous
cohorts of children with epilepsy. This ﬁnding was not supported
by some studies,21 which have found that remaining discharges
after withdrawal did not predict the occurrence of a relapse.
Some of the other investigated variables, although not
signiﬁcantly related to relapse rate, deserve attention. Seizure-
free period of median four years before withdrawal did not
inﬂuence the relapse risk. This ﬁnding correlates with the study of
Ohta et al.8, although the seizure-free cut-off period was six years.
Verrotti et al.6 suggested safe AED discontinuation in children with
CFE who were seizure-free for only one year. This could not be
conﬁrmed by our study. Some studies18,19 have reported seizure-
free periods shorter than four years as a seizure relapse risk factor
in children.
Having secondarily generalized seizures, as well as epileptic
status, through the course of the disease, did not inﬂuence the
relapse risk, which correlates to the ﬁnding of Ohta et al.8
Contrary to the ﬁndings in that study, patients treated by
polytherapy vs. monotherapy were not under signiﬁcantly
higher risk for relapse rate. We could not conﬁrm signiﬁcant
effects of speciﬁc AED in monotherapy on seizure relapses after
AED withdrawal.
4.4. Limitations of the study
Some additional hidden confounders might inﬂuence our data,
apart from those already discussed earlier. First, referral pattern
can be a source of selection bias. Although the setting of the study
assumes more patients whose epilepsy could not be controlled
easily, common referral pattern does not include only the difﬁcult-
to-treat cases. Hence, we believe the patients reasonably fairly
reﬂect the wider population of children with CFE.
Second, regarding our diagnostic concerns to exclude symp-
tomatic epilepsies, MR ﬁndings in most of the patients supported
our classiﬁcation. Patients lacking MR could only be veriﬁed as
non-lesional by CT brain studies. We are aware of limited CT
sensitivity and possibilities that epilepsies considered cryptogenic
can have some unrecognized subtle cortical dysplasia.22 We also
are aware that exclusion of thus-far recognized idiopathic focal
M. Pavlovic´ et al. / Seizure 21 (2012) 431–436436epilepsies leaves space for some other, to date not recognized focal
genetic epilepsy types.
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